Examination of the relationship between oncology drug labeling revision frequency and FDA product categorization

American Journal of Public Health

Volumn 99, Issue 9, 2009, Pages 1693-1698

  Berlin, Robert J ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Hogan and Hartson   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CONTROLLED STUDY; DRUG APPROVAL; DRUG INFORMATION; DRUG LABELING; FOOD AND DRUG ADMINISTRATION; TRADITIONAL MEDICINE;

ANTINEOPLASTIC AGENTS; DRUG APPROVAL; DRUG INDUSTRY; DRUG LABELING; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 69049105433     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2008.141010     Document Type: Article

References (20)

1. US Food and Drug Administration. FDA's mission statement. Available at: http://www.fda.gov/opacom/morechoices/mission.html. Accessed November 21, 2008.
2. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). CDER home page. Available at: http://www.fda.gov/cder/index.html. Accessed November 21, 2008.
3. Federal Register 58942 (1992).
4. 21 CFR §314.510 (2000).
5. Prescription Drug User Fee Act of 1992, Pub L No. 102-571 (1992).
6. Center for Drug Evaluation and Research. Review management: priority review policy. August 10, 2007. Available at: http://www.fda.gov/cder/mapp/6020. 3R.pdf. Accessed November 21, 2008.
7. US Food and Drug Administration. Fast track, accelerated approval and priority review. Available at: http://www.fda.gov/oashi/fast.html. Accessed November 21, 2008.
8. The Orphan Drug Act, Pub L No. 97-414 (1983).
9. 21 USC 360bb (1997).
10. US Food and Drug Administration, Office of Orphan Products Development (OOPD). OOPD frequently asked questions. Available at: http://www.fda.gov/ orphan/faq/index.htm. Accessed November 21, 2008.
11. 21 CFR §316.31 (2007).
12. Food and Drug Administration Modernization Act of 1997, Pub L No. 105-115 (1997).
13. US General Accounting Office. FDA drug review: postapproval risks 1976-85 (1990). Available at: http://161.203.16.4/d24t8/141456.pdf. Accessed November 21, 2008.
14. 21 CFR pt 201 (2007).
15. US Food and Drug Administration, Center for Drug Evaluation and Research. List of approved oncology drugs with approved indications. Available at: http://www.fda.gov/cder/cancer/druglistframe.htm. Accessed November 21, 2008.
16. US Food and Drug Administration, Center for Drug Evaluation and Research. Fast track, priority review and accelerated approval. Available at: http://www.accessdata.fda.gov/scripts/cder/onctools/Accel.cfm. Accessed November 21, 2008.
17. US Food and Drug Administration, Center for Drug Evaluation and Research. Orphan Drug Designation. Available at: http://www.accessdata.fda.gov/scripts/ cder/onctools/orphan.cfm. Accessed November 21, 2008.
18. US Food and Drug Administration, Center for Drug Evaluation and Research. Drugs@FDA: FDA approved drug products. Available at: http://www.accessdata.fda. gov/scripts/cder/drugsatfda/index.cfm. Accessed November 21, 2008.
19. US Food and Drug Administration, Center for Drug Evaluation and Research. Cumulative list of all products that have received orphan designation. Available at: http://www.fda.gov/orphan/designat/alldes.rtf. Accessed March 17, 2009.
20. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). CDER Drug and Biologic Approval Reports. Available at: http://www.fda.gov/cder/rdmt/default.htm. Accessed March 17, 2009.